This presentation on research about HIV self-testing in Australia was given by A/Prof Rebecca Guy, The Kirby Institute, at the AFAO Members Forum - May 2015.
This presentation on research about HIV self-testing in Australia was given by A/Prof Rebecca Guy, The Kirby Institute, at the AFAO Members Forum - May 2015.
10 most trusted clinical laboratories in 2021Merry D'souza
To honor the diligent services of clinical laboratories, we came up with this edition of Insights Care - 10 Most Trusted Clinical Laboratories in 2021.
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.CBRC
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey. Presented by Mark Gilbert, BC CDC, at the 5th Annual Gay Men's Health Summit held in Vancouver, BC on November 9th and 10th, 2009.
Evolving Switch Strategies for Virologically Suppressed HIV-Infected Patients...Hivlife Info
Доктор David A. Wohl при участии группы экспертов, рассматривает основные исследования о том, когда и как, при каких условиях переводить пациентов со стабильной супрессией ВИЧ на новые методы лечения .
Случаи и разногласия по ВИЧ в 2019 году: европейские перспективы / Cases and...hivlifeinfo
Learn unique perspectives across Europe on PrEP, rapid ART initiation, ART in women, and options for switching ART.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.33 MB
Released: July 10, 2019
Ségolème Aymé - Infraestructuras de I + D para impulsar investigación en Enfe...Fundación Ramón Areces
El 29 de octubre de 2014, la Fundación Ramón Areces celebró una nueva conferencia del ciclo de Enfermedades Raras organizado con el Vall d'Hebron Institute of Research de Barcelona. En esta ocasión, Ségolène Aymé, directora emérita de investigación del INSERM, fundadora de Orphanet y presidenta del Grupo Consultivo Temático sobre Enfermedades Raras en la OMS, habló sobre 'Las infraestructuras de I+D necesarias para impulsar la investigación en Enfermedades Raras'. Antes de su intervención, explicó en esta entrevista cómo mejorar las políticas de investigación en patologías poco frecuentes.
Phillip Keen (Kirby Institute) discusses the successes and challenges of community-based HIV testing.
This presentation was given at the AFAO National HIV Forum, 17 October 2014.
The Percepta Bronchial Genomic Classifier uses advanced genomic technology to improve lung cancer diagnosis for patients, reducing the need for invasive procedures that can follow when potentially cancerous lung nodules or lesions are found on CT scans. Lung cancer is the leading cause of cancer deaths in the United States, killing more than 154,000 Americans each year—more than the next three leading cancers combined.
n engl j med 368;24 nejm.org june 13, 2013 2319s o u n d i.docxrosemarybdodson23141
n engl j med 368;24 nejm.org june 13, 2013 2319
s o u n d i n g b o a r d
T h e n e w e n g l a n d j o u r n a l o f m e d i c i n e
How Point-of-Care Testing Could Drive Innovation
in Global Health
Ilesh V. Jani, M.D., Ph.D., and Trevor F. Peter, Ph.D., M.P.H.
The investment in health services in low- and mid-
dle-income countries has increased substantially
in recent years.1 Such investment has been led by
unprecedented efforts to combat major diseases,
enabled by the availability of lower-cost and effec-
tive drug regimens for treatment and prophylaxis,
along with improved vector control. As health
services have expanded, so has the demand for
diagnostic tests that are essential in identifying
patients, determining prognosis, monitoring treat-
ment, and assessing the efficacy of prevention.2
Classic diagnostic technologies are not well
suited to meeting the expanded testing needs.
Laboratory tests require complex infrastructure,
skilled technicians, and a stable supply of elec-
tricity, all of which are scarce, particularly in
nonurban areas. Traditional testing is usually
performed in remote laboratories, which increas-
es the cost and inconvenience of accessing health
care and leads to a high number of patients who
leave the system before a diagnosis is established.3
These limitations are a critical barrier to equity
in health services. Microscopy requires less in-
frastructure and is more widely available, but it
can be inaccurate (e.g., sputum tests for tubercu-
losis) or slow and underutilized (e.g., smear tests
for malaria, schistosomiasis, and other parasitic
infections).4-6 Many patients with tuberculosis or
malaria are simply treated on the basis of a pre-
sumptive clinical diagnosis. Although convention-
al laboratory testing and microscopy will still be
needed, it is expected that faster and more ac-
curate point-of-care diagnostic tests that do not
require laboratory infrastructure will play an in-
creasing role in expanding health care in low- and
middle-income countries.7
T h e S h if t t o w a r d P o in t- o f - C a r e
T e s t in g
Rapid point-of-care testing for diabetes, anemia,
pregnancy, human immunodeficiency virus (HIV),
and malaria have long been available and have be-
come common diagnostic tools in both high- and
low-income countries (Fig. 1). The first generation
of point-of-care testing relied on easy-to-detect
biomarkers, such as antibodies, antigens, and sim-
ple biochemical reactions. Such biomarkers are
also increasingly used in point-of-care tests for a
wide range of infectious diseases (e.g., syphilis,
hepatitis, measles, schistosomiasis, and tricho-
moniasis) and for applications such as blood
typing.8-11
A second generation of point-of-care diagnos-
tics is now on the horizon, partly because of re-
cent industry and donor investment. These tests
detect more complex and less accessible biomark-
ers, such as nucleic acids and cell-surface markers,
an.
10 most trusted clinical laboratories in 2021Merry D'souza
To honor the diligent services of clinical laboratories, we came up with this edition of Insights Care - 10 Most Trusted Clinical Laboratories in 2021.
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey.CBRC
HPV infection and anal dysplasia in Vancouver: findings from the ManCount Survey. Presented by Mark Gilbert, BC CDC, at the 5th Annual Gay Men's Health Summit held in Vancouver, BC on November 9th and 10th, 2009.
Evolving Switch Strategies for Virologically Suppressed HIV-Infected Patients...Hivlife Info
Доктор David A. Wohl при участии группы экспертов, рассматривает основные исследования о том, когда и как, при каких условиях переводить пациентов со стабильной супрессией ВИЧ на новые методы лечения .
Случаи и разногласия по ВИЧ в 2019 году: европейские перспективы / Cases and...hivlifeinfo
Learn unique perspectives across Europe on PrEP, rapid ART initiation, ART in women, and options for switching ART.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.33 MB
Released: July 10, 2019
Ségolème Aymé - Infraestructuras de I + D para impulsar investigación en Enfe...Fundación Ramón Areces
El 29 de octubre de 2014, la Fundación Ramón Areces celebró una nueva conferencia del ciclo de Enfermedades Raras organizado con el Vall d'Hebron Institute of Research de Barcelona. En esta ocasión, Ségolène Aymé, directora emérita de investigación del INSERM, fundadora de Orphanet y presidenta del Grupo Consultivo Temático sobre Enfermedades Raras en la OMS, habló sobre 'Las infraestructuras de I+D necesarias para impulsar la investigación en Enfermedades Raras'. Antes de su intervención, explicó en esta entrevista cómo mejorar las políticas de investigación en patologías poco frecuentes.
Phillip Keen (Kirby Institute) discusses the successes and challenges of community-based HIV testing.
This presentation was given at the AFAO National HIV Forum, 17 October 2014.
The Percepta Bronchial Genomic Classifier uses advanced genomic technology to improve lung cancer diagnosis for patients, reducing the need for invasive procedures that can follow when potentially cancerous lung nodules or lesions are found on CT scans. Lung cancer is the leading cause of cancer deaths in the United States, killing more than 154,000 Americans each year—more than the next three leading cancers combined.
n engl j med 368;24 nejm.org june 13, 2013 2319s o u n d i.docxrosemarybdodson23141
n engl j med 368;24 nejm.org june 13, 2013 2319
s o u n d i n g b o a r d
T h e n e w e n g l a n d j o u r n a l o f m e d i c i n e
How Point-of-Care Testing Could Drive Innovation
in Global Health
Ilesh V. Jani, M.D., Ph.D., and Trevor F. Peter, Ph.D., M.P.H.
The investment in health services in low- and mid-
dle-income countries has increased substantially
in recent years.1 Such investment has been led by
unprecedented efforts to combat major diseases,
enabled by the availability of lower-cost and effec-
tive drug regimens for treatment and prophylaxis,
along with improved vector control. As health
services have expanded, so has the demand for
diagnostic tests that are essential in identifying
patients, determining prognosis, monitoring treat-
ment, and assessing the efficacy of prevention.2
Classic diagnostic technologies are not well
suited to meeting the expanded testing needs.
Laboratory tests require complex infrastructure,
skilled technicians, and a stable supply of elec-
tricity, all of which are scarce, particularly in
nonurban areas. Traditional testing is usually
performed in remote laboratories, which increas-
es the cost and inconvenience of accessing health
care and leads to a high number of patients who
leave the system before a diagnosis is established.3
These limitations are a critical barrier to equity
in health services. Microscopy requires less in-
frastructure and is more widely available, but it
can be inaccurate (e.g., sputum tests for tubercu-
losis) or slow and underutilized (e.g., smear tests
for malaria, schistosomiasis, and other parasitic
infections).4-6 Many patients with tuberculosis or
malaria are simply treated on the basis of a pre-
sumptive clinical diagnosis. Although convention-
al laboratory testing and microscopy will still be
needed, it is expected that faster and more ac-
curate point-of-care diagnostic tests that do not
require laboratory infrastructure will play an in-
creasing role in expanding health care in low- and
middle-income countries.7
T h e S h if t t o w a r d P o in t- o f - C a r e
T e s t in g
Rapid point-of-care testing for diabetes, anemia,
pregnancy, human immunodeficiency virus (HIV),
and malaria have long been available and have be-
come common diagnostic tools in both high- and
low-income countries (Fig. 1). The first generation
of point-of-care testing relied on easy-to-detect
biomarkers, such as antibodies, antigens, and sim-
ple biochemical reactions. Such biomarkers are
also increasingly used in point-of-care tests for a
wide range of infectious diseases (e.g., syphilis,
hepatitis, measles, schistosomiasis, and tricho-
moniasis) and for applications such as blood
typing.8-11
A second generation of point-of-care diagnos-
tics is now on the horizon, partly because of re-
cent industry and donor investment. These tests
detect more complex and less accessible biomark-
ers, such as nucleic acids and cell-surface markers,
an.
Adherence to Antiretroviral Therapy among HIVPositive Patients in Central Hos...Efe Clement Abel
Abstract: Adherence is the quantified level to which an individual follows a prescribed treatment and a low level of adherence to antiretroviral therapy(ART) adversely affects a patient’s treatment outcome and results in a rebound of plasma viraemia, development of resistant strains of HIV, more rapid immune deterioration, development of AIDS and death. This study is aimed at assessing the level of adherence to ART among HIV-positive patients assessing care in Central Hospital, Warri, Delta State, Nigeria. A descriptive cross-sectional study. Data were obtained using a semi-structured, interviewer-administered questionnaire and analysed using SPSS version 23. A total of 303 persons were recruited for the study. The mean age of respondents was 36.2±10.8years. Less than half of the subjects (45.5%) were adherent to their ART. Among the non-adherent subjects, the common reasons reported for missing doses of ART were forgetfulness (50.9%), too busy with other things (43.6%) and away from home (35.8%). This study showed that adherence to ART among the study population was poor. Forgetfulness, too busy with other things and being away from home were the most common reason for non-adherence. It is, therefore, recommended that; regular health education should be organised for HIV patients on ART on the importance of being adherent to their ART, regular assessment of adherence to ART should be carried out and a method of reminding patients who are non-adherent to ART on the need to take their ART as at when due should be considered as part of the routine services provided by ART centres.
How evidence affects clinical practice in egyptWafaa Benjamin
Evidence based medicine is the gold standard for clinical care.
It implies the integration of best research evidence with clinical expertise and patient values.
There is still a wide gap between availability of evidence and its incorporation into routine practice in our country.
Barriers to implementation could be personal, social, institutional, financial and legal barriers.
True practice of evidence based care can only occur where evidence based decisions coincide with patients’ beliefs and clinicians’ preferences.
Continuing medical education programs should be set with integrating evidence based medicine teaching and learning within clinical training.
The importance of presence of local national guidelines which need to take into account variation in expertise, resources and patient preferences across our geographical and cultural contexts .
Customisation of a guideline to meet the local needs of a target patient population is critical to successful implementation.
Conduct of clinical Trials during covid 19 a CTTI webinar Pamela Tenaerts
This week, stakeholders from across the clinicaltrials ecosystem submitted experiences and insights related to the FDA’s new guidance on the #conduct of clinical trials of medical products during the current hashtag#COVID-19 pandemic. We shared best practices and experiences in a webinar and our slides are now available in advance of posting the webinar.
Heavily based on a presentation I gave for the CMS 2020 National Quality Forum. Emphasis is on dialysis (particularly home dialysis). Discusses regulatory framework, medical devices used to render the services and outcomes of studies performed to day
Similar to Launch of Policy Cures: Improving Access to Diagnostics in the Developing World - Professor Rosanna Peeling (20)
Patricia Latter REF "Routes to Impact" presentation 26/05/2016LIDC
This event, “REF: routes to impact”, aimed to raise awareness among academic members of the multiple routes to impact their research can have. The aim of the evening was to let researchers consider the numerous ways that research can have an impact within an international development context.
Ian thornton REF "Routes to Impact" presentation 26/05/2016LIDC
This event, “REF: routes to impact”, aimed to raise awareness among academic members of the multiple routes to impact their research can have. The aim of the evening was to let researchers consider the numerous ways that research can have an impact within an international development context.
The UK Research Councils will deliver through the GCRF £1.5b in research grants for international development research over the next five years. This funding is new and additional to existing sources of research support like DFID, the Newton Fund, etc., which will continue. The GCRF represents the largest single boost to research council funding in their history and will create an entirely new stream of development research funding across arts, humanities, social and natural sciences, with particular opportunities for interdisciplinary research.
Malcolm Potts Crisis in the Sahel: Where Population and Climate Change Are Co...LIDC
rofessor Malcolm Potts, renowned in the field of public health, gave a one-off keynote lecture for LIDC. The lecture, at the London School of Hygiene and Tropical Medicine, focused on the emerging humanitarian disaster in the Sahel. It has been central to the work of his team for several years.
An Interdisciplinary Perspective on Global Health and the SDGs - Prof. Sir An...LIDC
It is rare that you find an outstanding leader in a particular discipline who has also become as well an international figure in interdisciplinary thinking. Prof Sir Andy Haines is just such a figure.
A former Director of the London School of Hygiene and Tropical Medicine and one of the designers and founders of LIDC about a decade ago, Andy has in recent years developed an international reputation and programme linking our development agenda for global health with the much bigger challenge of sustainability and the threat posed to that by climate change and environmental degradation.
His work has revealed the threats posed to health and well being by environmental change, but has emphasized and identified the positive opportunities, and the co-benefits they can generate.
Model Attribute Check Company Auto PropertyCeline George
In Odoo, the multi-company feature allows you to manage multiple companies within a single Odoo database instance. Each company can have its own configurations while still sharing common resources such as products, customers, and suppliers.
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
How to Make a Field invisible in Odoo 17Celine George
It is possible to hide or invisible some fields in odoo. Commonly using “invisible” attribute in the field definition to invisible the fields. This slide will show how to make a field invisible in odoo 17.
Honest Reviews of Tim Han LMA Course Program.pptxtimhan337
Personal development courses are widely available today, with each one promising life-changing outcomes. Tim Han’s Life Mastery Achievers (LMA) Course has drawn a lot of interest. In addition to offering my frank assessment of Success Insider’s LMA Course, this piece examines the course’s effects via a variety of Tim Han LMA course reviews and Success Insider comments.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
Overview on Edible Vaccine: Pros & Cons with Mechanism
Launch of Policy Cures: Improving Access to Diagnostics in the Developing World - Professor Rosanna Peeling
1. Improving Access To Diagnostics in the Developing World Rosanna Peeling Professor and Chair, Diagnostics Research London School of Hygiene & Tropical Medicine
2. Improving Access To Diagnostics in the Developing World Global landscape of diagnostics Improving access to diagnostic innovation Fast-tracking the translation of evidence to policy
3.
4. Diagnostics are Under-valued In the US, while diagnostics comprise - less than 5% of hospital costs - about 1.6% of all Medicare costs, their findings influence as much as 60-70% of health care decision-making The Value of Diagnostics, Lewin Report, 2005
5.
6.
7. How Good are Dengue Rapid Tests? WHO Evaluation (%) SensSpec 23 99 18 98 63 69 9 100 65 98 22 99 6 99 Test Claimed Accuracy (%) Sens Spec Test 1 100 100 Test 2 NS NS Test 3 80 >99 Test 4 NS NS Test 5 70 100 Test 6 93 100 Test 7 100 100 NS = not stated Blacksell et al. Clin Infect Dis 2006;42:1127
8. Product Development and Adoption Pathway for Diagnostics Regulatory Approval Diagnostic Targets Proof of Principle Product Prototype Lab & field evaluations Test adoption Policy & Guidelines Product Specifications Technology platform Shared Resources Shared Risks Shared Rewards
9. Lab on a Chip Platform: Integrated specimen processing, amplification, and detection of MTB and Rif resistance in sputum In < 2 hrs In 1,730 patients with suspected drug-sensitive or multi drug-resistant pulmonary TB at centers in Peru, Azerbaijan, South Africa, and India, Xpert detected 98% of smear +, 90% of smear – ; 98% of RIF resist. and 98% of RIF sens. TB. Boehme et al NJEM Sept 6 2010
